

# Revealing Melatonin's Mysteries: Receptors, Signaling Pathways, and Therapeutics Applications

## Authors

Kulsoom<sup>1</sup>, Wajahat Ali<sup>2</sup> , Zainab Saba<sup>3</sup>, Shabab Hussain<sup>4</sup>, Samra Zahra<sup>5</sup>, Maria Irshad<sup>6</sup>, Muhammad Saeed Ramzan<sup>7</sup>

## Affiliations

- 1 Department of Biochemistry, Bahauddin Zakariya University, Multan, Pakistan
- 2 School of Basic Medical Sciences, Xi'an Jiaotong University, Xian, China
- 3 Department of Optometry, Khwaja Fareed University of Engineering & Information Technology, Rahim Yar Khan, Pakistan
- 4 Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, Universita degli studi di Messina, Messina, Italy
- 5 Department of Biosciences, COMSATS University Islamabad, Pakistan
- 6 Department of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy
- 7 Department of Pharmacology, The Islamia University of Bahawalpur, Bahawalpur, Pakistan

## Keywords

melatonin, receptor structure, receptor signaling cascade, pineal gland

received 04.08.2023

accepted after revision 11.12.2023

accepted manuscript online 11.12.2023

published online 19.02.2024

## Bibliography

Horm Metab Res 2024; 56: 405–418

DOI 10.1055/a-2226-3971

ISSN 0018-5043

© 2024, Thieme. All rights reserved.

Georg Thieme Verlag KG, Rüdigerstraße 14,  
70469 Stuttgart, Germany

## Correspondence

Wajahat Ali  
Xian Jiaotong University  
School of Basic Medical Sciences  
Health Science Centre  
Building 21, Lab No. 1076, I Habor Campus  
710000 Xian  
China  
Tel.: + 8613227701806  
aliwajahat@stu.xjtu.edu.cn

## ABSTRACT

Melatonin (5-methoxy-acetyl tryptamine) is a sleep-inducing hormone, and the pineal gland produces it in response to the circadian clock of darkness. In the body, MT1 and MT2 receptors are mostly found, having an orthosteric pocket and ligand binding determinants. Melatonin acts by binding on melatonin receptors, intracellular proteins, and orphan nuclear receptors. It inhibits adenylyl cyclase and activates phospholipase C, resulting in gene expression and an intracellular alteration environment. Melatonin signaling pathways are also associated with other intracellular signaling pathways, i. e., cAMP/PKA and MAPK/ERK pathways. Relative expression of different proteins depends on the coupling profile of G protein, accounting pharmacology of the melatonin receptor bias system, and mediates action in a Gi-dependent manner. It shows antioxidant, antitumor, antiproliferative, and neuroprotective activity. Different types of melatonin agonists have been synthesized for the treatment of sleeping disorders. Researchers have developed therapeutics that target melatonin signaling, which could benefit a wide range of medical conditions. This review focuses on melatonin receptors, pharmacology, and signaling cascades; it aims to provide basic mechanical aspects of the receptor's pharmacology, melatonin's functions in cancer and neurodegenerative diseases, and any treatments and drugs designed for these diseases. This will allow a basic comparison between the receptors in question, highlighting any parallels and differences that may exist and providing fundamental knowledge about these receptors to future researchers.

## Introduction

Melatonin, chemically 5-methoxyacetyl tryptamine, is a sleep-inducing hormone, and in 1958, it was extracted from a pineal gland [1]. Its concentration is high at night time in all species. Animals' endogenous circadian clock, which secretes the hormone melatonin at night, is synchronized by light and dark cycles in the suprachiasmatic nucleus of the hypothalamus. In a 24-hour cycle, the pineal gland releases the hormone melatonin. When the retina detects stimuli of darkness, it is perceived by the suprachiasmatic nucleus, which generates a signal in the form of a nerve impulse and sends it to the upper thoracic cord of the intermediolateral column, then perceived by the superior cervical ganglion. After adrenergic stimuli, pineocytes of the pineal gland synthesize the melatonin hormone intracellularly. Neurological and physiological processes are regulated by melatonin. Photoperiodic species show seasonal changes regulated by the melatonin hormone in the hypothalamus, the pituitary pars tuberalis. It exerts direct action on the suprachiasmatic nucleus and entrains the circadian clock.

Circadian rhythm disorders, that is, jet lag, shift work, blindness, and delayed or advanced sleep phase syndromes, are treated by the response exerted by the melatonin hormone [2]. Dopamine synthesis is repressed from the retinal amacrine cells by melatonin [3] and can promote vasoconstriction in the rat tail artery [4]. Melatonin has also played a well-established hypnotic action. It triggers the opening of the sleep gate, which is circadian-dependent and initiates sleeping [5]. Melatonin mediates action as an antioxidant and influences immune function. Sleep and wake rhythm are induced by melatonin [6]. The physiological processes, such as regulating the cardiovascular system, are controlled by melatonin [7] and buffering of the immune system and neurodegenerative disorders [8]. In drug designing, the therapeutic agents are designed that target melatonin targets. Melatonin plays a role in cancer protection, confirmed by research, also bone formation and glucose maintenance [9].

## Synthesis of melatonin hormone

The synthesis of melatonin involves a two-step process from the pineal gland

- Arylalkylamine is used for serotonin acetylation by using acetyltransferase enzyme to produce acetylserotonin,
- Melatonin is synthesized by the enzyme hydroxyindole-O-methyltransferase by methylation of the 5-hydroxy group (► **Table 1**, ► **Fig. 1**).

## Excretion of melatonin

Mainly in the liver, melatonin is metabolized most efficiently but to some extent in the kidney. Melatonin is oxidized into 6-hydroxymelatonin in the liver by the cytochrome P 450 enzyme, and 6-hydroxymelatonin is then conjugated with sulfuric acid to 6-sulfatoxymelatonin [10]. In the form of 6-sulfatoxymelatonin, it is eliminated from the body through urination (► **Table 2**), which is a major melatonin metabolite used to access melatonin concentration in the plasma [11].

## Mechanism of melatonin effects

In mammals, the effects of melatonin are revealed by four different mechanisms:

1. Melatonin acts as an antioxidant
2. Melatonin binds to plasma membrane receptors
3. Interaction of melatonin to intracellular proteins, that is, calmodulin
4. Orphan nuclear receptors are targeting [12]

Intracellular proteins, that is, calmodulin, calreticulin, and tubulin, interact with melatonin. The binding of calcium to calmodulin, an intracellular second messenger, is antagonized by melatonin [13]. Melatonin shows regulation of antiproliferative effects in cancer. Melatonin shows immunomodulatory effects, which is mediated by retinoid-related orphan nuclear receptor (► **Fig. 2**). Mononuclear cells secrete interleukins IL-2 and IL-6 owing to this modulation [14].

## Melatonin receptors

Melatonin receptors are present on the plasma membrane of different cells, that is, cells of the immune system, cells of the coronary artery, cells of the cardiac ventricular wall, cells of the cardiovascular system, appendix vermiform, hepatocytes, gallbladder, duodenal enterocytes, aorta cells of the large intestinal cecum, colon, skin cells, fetal kidney, kidney, platelets, brain, retina, parotid gland, cells of cerebral arteries, exocrine pancreas, breast and prostate epithelial cells, placenta, epithelial cells of breast, cells of the ovary, myometrium, and brown adipocytes. The morphology of white adipocytes is different from each other [15]. Jejunal and colonic mucosal cells possess melatonin receptors. Melatonin receptors are of four different types in living organisms in different cells as shown in ► **Table 3**. Three receptors are on the plasma membrane, while one is the nuclear receptor.


### Type 1a receptor

These are primarily present in human skin cells, consisting of 351 amino acids and encoded by a gene on chromosome #4. It has five different receptor subtypes: MT1, MTNR1A, Mel1a, ML1a, and ML1 [16]. The binding of type 1 melatonin receptors to different types of GPCRs inactivates adenylyl cyclase [17]. These receptors' expression is decreased in the cortex and suprachiasmatic nucleus during Alzheimer's and aging [18], suppressing protein secretion and neuronal discharge in the suprachiasmatic nucleus [19].

### Type 1b receptor

The gene for this receptor is present on chromosome #11, encoding a polypeptide of 363 amino acids. It has three different receptor subtypes: MTNR1B, ML1b, and MT2 [6]. The binding of this receptor to different GPCRs inactivates adenylyl cyclase and guanylyl cyclase [17]. cAMP synthesis is decreased by inactivating adenylyl cyclase [20]. These receptors are located in sweat glands and malign melanocytes [21]. These receptors inhibit gamma amino butyric acid A receptors in rat hippocampus [22]. Showing antidepressant properties reveals that their expression decreased in Alzheimer's disease [15], depression and sleep diseases are associated with abnormal melatonin receptors, and pharmacology and pathophys-

► **Table 1** Synthetic and Metabolic Pathway of Melatonin.



iology of Alzheimer's and anxiety diseases are associated with abnormality in these receptors. These receptors are the new target for hypotonic agents. Anxiety and sleep cycles are regulated by these receptors. MT1/MT2 does not possess hypotonic effects as compared to these receptors [17].

### MTNR1C and Mel1c

These receptors are present in fish, birds, and amphibians but not in humans. The chicken MT1 and MT2 receptors are antagonistic to this receptor's circadian rhythm. In the daytime, it is present in high and low concentrations at night [6].

### MT3

This receptor shows antioxidant properties due to the quinone reductase-2 enzyme and inhibits the electrons transfer reaction of quinone. Melatonin type 3 receptors and detoxification quinone reductase 2-enzyme are present on the plasma membrane of muscle, brown fat tissue, liver, kidney, heart, lung, and intestinal cells. Intraocular pressure is regulated by it [18].

### RZR/ROR $\alpha$

These nuclear receptors help bind melatonin to transcription factors in the nucleus and belong to the retinoic acid receptor super T family [23]. This receptor consists of 618 amino acids encoded by chromosome #28. This receptor does not bind to melatonin and is present in all mammals; it helps bind melatonin to MT [6].

## A Melatonin as receptor


### Ligand selectivity determinants and orthosteric

The orthosteric pocket created by TM3, TM5, TM6, TM7, and ECL2 in the structures of both MT1 and MT2 binds ramelteon and 2-iodomelatonin (► Fig. 3, 4a,c). It is possible to superimpose the ramelteon's binding pose with that of inactive structures in active


► **Table 2** MT1 and MT2 Receptor's distribution in Human.

Receptor type		Tissues	Reference		
hMT1	Brain	Cerebellum	[23]		
		Occipital cortex	[24]		
		Parietal cortex	[23]		
		Temporal cortex	[23]		
		Thalamus	[23]		
		Frontal cortex	[23]		
	Peripheral tissues	Hippocampus	[23]		
		SCN	[25]		
		Retina	[27]		
		Brown and white adipose tissue	[28]		
		Fetal kidney	[29]		
		Coronary artery	[30]		
		Granuloma cells	[31]		
		Myometrium	[32]		
		Pancreatic alpha and beta cells	[33]		
		Testis	[34]		
		hMT2	Brain	Cerebellum	[24]
				Hippocampus	[25]
SCN	[26]				
	Peripheral tissues	Retina	[27]		
		Brown and white adipose tissue	[28]		
		Fetal kidney	[29]		
		Granulosa cells	[30]		
		Placental tissues	[31]		
		Myometrium	[32]		
		Pancreatic alpha and beta cells	[33]		
		Testis	[34]		

MT1 or MT2. But the active form of 2-iodomelatonin changes slightly from the inactive form, especially where the alkyl amide tail is concerned, where it approaches the W6.48 residue in functioning MT1, which acts as a "toggle switch." ECL2 consistently occupies the pocket's top position in both conformations, blocking ligand accessibility through the extracellular side (► Fig. 4b, d). The only access point to the orthosteric-binding site in the active conformation has been discovered to be the lateral channel between TM4 and TM5. It was discovered that the only access point to the orthosteric-binding site in the active conformation is the lateral channel between TM4 and TM5 (► Fig. 4b, d). The orthosteric pocket is more constrained in the center of active structures, but TM3, TM4, and TM5 in dormant structures make a large "longitudinal channel" that this fiber bundle grows to join. While the residues around the iodine group and alkyl amide tail (referred to as the R3



► **Fig. 1** Synthesis of melatonin through the neurologic pathway from the pineal gland and its effects.



► **Fig. 2** MT1-Gi and MT2-Gi complex structures: The complexes are shown by Cryo-EM density maps. Panel **a**: Blue color represents melatonin type 1 receptors; green color represents melatonin type 2; green; purple represent G $\alpha$ i in MT1; yellow represent G $\alpha$ i in melatonin type 2; scFV16, violet is color code. G $\beta$ , teal; G $\gamma$ , light green. Panel **b** shows the cryo-EM structure of MT1-Gi and MT2-Gi. The left side shows 2-iodomelatonin-bound MT1-Gi; the middle side shows ramelteon-bound MT1-Gi; the right side shows ramelteon-bound MT2-Gi. The top right side shows the structure of ligands and melatonin molecules.

position in melatonin, ► **Fig. 5**) match up well, the active pocket's structure might vary depending on the conformations of the residues flanking the solvent channel (► **Fig. 4e, f**). A hydrogen bond


is formed between the aromatic residue Y1875.38 in MT1 and N1624.60 in the active structure by rotating from the inactive structure's solvent-facing conformation toward TM4.

► **Table 3** Mysteries of Melatonin hormone reported in various human systems and processes.

Mysteries of Melatonin	Reference
<b>Circadian Rhythms and Melatonin</b>	[8]
<ul style="list-style-type: none"> <li>Regulate sleep and wake cycle</li> <li>Influence on circadian rhythms</li> </ul>	
<b>Melatonin Receptors Functions</b>	
<ul style="list-style-type: none"> <li><b>Type 1a and 1b receptors</b> expression is decreased in the cortex and suprachiasmatic nucleus during Alzheimer's and aging, suppressing protein secretion and neuronal discharge in the suprachiasmatic nucleus and inhibiting GABA showing antidepressant.</li> </ul>	[15, 16, 18–19]
<ul style="list-style-type: none"> <li><b>MT3 receptor</b> shows antioxidant properties due to the quinone reductase-2 enzyme and inhibits the electrons transfer reaction of quinone.</li> </ul>	[22]
<ul style="list-style-type: none"> <li><b>RZR/ROR<math>\alpha</math> nuclear receptors</b> help bind melatonin to transcription factors in the nucleus and belong to the retinoic acid receptor super T family.</li> </ul>	[15]
<b>Melatonin Receptors as a Drug Target</b>	
<ul style="list-style-type: none"> <li><b>Type 1a and 1b receptors</b> are the new target for hypotonic agents. Anxiety and sleep cycles are regulated by these receptors.</li> <li><b>Ligand Selectivity Determinants and Orthosteric of MT2</b> has N4.60-Y5.38-H5.46 motif, the longitudinal channel, and the larger subpocket could all be used as targets for the designing of melatonin subtype-selective drugs.</li> <li><b>Therapeutic agents</b> are designed that target melatonin targets</li> </ul>	[11, 18]
<b>Therapeutic Applications</b>	
<b>Melatonin and Immunomodulation</b>	[14]
<ul style="list-style-type: none"> <li>Secrete interleukins IL-2 and IL-6</li> </ul>	
<b>Melatonin and Cardiovascular System</b>	
<ul style="list-style-type: none"> <li>Reduces high serum total cholesterol and triglyceride levels in the blood</li> <li>Improve lipid metabolism by decreasing low-density lipoprotein</li> <li>Decrease systolic and diastolic blood pressure at night</li> <li>Decrease nocturnal systolic blood pressure</li> <li>Reduce the severity of cardiac marker injury and myocardial infarction size</li> <li>Lower heart rate by increasing ejection fraction</li> <li>Improves blood pressure, glycemic index, and lipid in patients suffering from chronic heart diseases</li> <li>Reduce cardiac fibrosis in nonischemic heart failure. Its intake prevents myocardial infarction</li> </ul>	[67–69]
<b>Melatonin and Nervous System</b>	
<ul style="list-style-type: none"> <li>Decrease infarct volume and brain edema and improving neurologic score</li> <li>Improve sleep quality and cognitive function in the brain</li> <li>Treats sleep disorders associated with amnesia, sundowning, and Alzheimer's diseases</li> <li>Delay the degeneration of dopaminergic neurons in the substantia nigra in the treatment of Parkinson, Cognitive dysfunction, anxiety, depression</li> <li>Improve sleep behavior in epilepsy patients</li> <li>Treat migraine and prophylaxis in both adults and children</li> <li>Improve sleep quality and prevents headache and tension</li> <li>Treat sleep disturbances in patients with traumatic brain injury</li> </ul>	[71–77]

► **Table 3** continued.

Mysteries of Melatonin	Reference
<b>Reproductive System</b>	
<ul style="list-style-type: none"> <li>Enhance the corpus cavernosum's ability to contract and relax</li> <li>Improves endothelial density and erectile function</li> <li>Improves fertilization rate</li> <li>Increases progesterone production in the corpus luteum</li> </ul>	[78–79]
<b>Gastrointestinal System</b>	
<ul style="list-style-type: none"> <li>Protect against mucosa oxidative damage in different types of gastrointestinal tract ulcers</li> <li>Reduces relaxation duration, and increases gastrin</li> <li>Decrease abdominal pain, bloating, and constipation and increases rectal pressure</li> <li>Lowers liver cholesterol, triglycerides, serum AST and ALT levels in hepatic steatosis patients</li> <li>Treat Hemorrhagic shock, ischemia-reperfusion injury, liver damage, ionizing radiation, and Schistosoma mansoni infection</li> </ul>	[80, 83]
<b>Renal System</b>	
<ul style="list-style-type: none"> <li>Protect against radiation, folic acid, aminoglycoside, contrast-mediated, and nephrotoxicity induced by these agents</li> <li>Reduce creatinine and blood urea nitrogen levels</li> <li>Decreases inflammasome activation</li> </ul>	[84–85]
<b>Dermatology</b>	
<ul style="list-style-type: none"> <li>Protect against UV-light-induced damage by preventing the production of free radicals, erythema caused by natural sunlight, and radioprotective effects</li> <li>Anti-aging properties, enhances hydration, and lessens the roughness of the skin</li> </ul>	[86]
<b>Fibromyalgia</b>	
Improves pain level and fibromyalgia	
<b>Autism Spectrum Disorder</b>	
<ul style="list-style-type: none"> <li>Lowers mid-sleep awakenings,</li> <li>Improves sleep quality, and lengthens total sleep time</li> </ul>	[88]
<b>Mood Disorder</b>	
<ul style="list-style-type: none"> <li>Diminishes sleep disorders linked to a depressed mood</li> </ul>	[89]
<b>Oncology</b>	
<ul style="list-style-type: none"> <li>Melatonin adjuvant therapy for ER-positive breast cancer</li> <li>Provides protection to ovaries and fertility preservation</li> <li>Lessen radiation-induced lung injury</li> <li>Modulates the effectiveness of DNA repair in humans as well as the genotoxic activity of irinotecan</li> <li>Ursolic acid has antiproliferative and pro-apoptotic effects on colon cancer cells</li> </ul>	[90–93]
<b>Viral Syndromes</b>	
<ul style="list-style-type: none"> <li>Reduce the acute lung oxidative injury by respiratory syncytial virus</li> <li>Preservation of cardiac functions and for repression of virus-induced cardiomyocyte apoptosis</li> <li>Inhibits apoptosis, regulates the rate of autophagy, and maintains mitochondrial dysfunction</li> <li>Increases survival rate by reducing virus load in the brain and serum</li> <li>Treat encephalomyelitis by preventing death and paralysis</li> <li>Treat viremia and postpones disease</li> <li>Prolongs survival time by reducing oxidative damage and slowing down the release of cytokines</li> </ul>	[94–99]
<b>Circadian Rhythm Disorders</b>	
<ul style="list-style-type: none"> <li>Treat jet lag, shift work, blindness, and delayed or advanced sleep phase syndromes</li> </ul>	[4]




**▶ Fig. 3** Ligand-binding pocket and selectivity of determinants: **a**: MT1 has a ligand-binding pocket (yellow) where 2-iodomelatonin (yellow) is bound (blue). **b**: Active (left) and inactive (right) forms of the ligand access channel MT1 are shown in the slab view (right, light blue, PDB ID: 6ME4). Ramelteon (pink) is attached to the ligand-binding pocket in MT2 (green). Schematic slab views of the active (left) and inactive (right) forms of the MT2 ligand access channel (right, light cyan, PDB ID: 6ME9). Ligand-binding residues of MT1 are shown in blue, while those of inactive ligand-binding pockets are shown in a lighter shade of blue. Red arrows indicate alterations of note. N162 and Y187 form a 3-f orbital distance hydrogen bond. The ligand-binding pockets of active (green) and inactive (light cyan) MT2 are contrasted. Red arrows indicate changes of significance. Active MT1 has g 5-HEAT docked in it (cyan). Key residues that are causing problems in this pocket are shown as sticks. In the open MT1, salmon CTL 01–05-B-A05 has successfully spawned. The red circle denotes the hydrophobic packing of the naphthalene group and F1945.45. MT2 was open when salmon CTL 01–05-B-A05 swam in. The naphthalene group and I2075.45 are packed incompatibly, as indicated by the red circle. **j**: Comparison of the sub-pockets from MT1 and MT2 that are active and bound to ramelteon (red in MT1, yellow in MT2). Sticks represent important distinct residues.

Furthermore, the hydrogen bond's diameter of the ligand entry is decreased, which may inhibit the unbinding of the bound agonist because the Y1875.38 A mutation caused a high ligand dissociation rate. The functional relevance of this proton pair in MT1 activation was further demonstrated by the fact that the N1624.60 A mutation rendered MT1 inactive. Homologous pair N1754.60 and Y2005.38 also underwent structural changes in MT2 during the transition. This hydrogen bond's absence demonstrates that MT2 does not require an entrance-restricting hydrogen bond similar to the one found in MT1 for activation, which is consistent with the earlier finding that the N1754.60 protein does not need such a hydrogen bond [24, 25]. No functional consequences resulted from a mutation [26]. Because N4.60-Y5.38 can be altered in conformation thanks to a conserved proline (P4.59) located close by in MT1 and MT2, changing P4.59 impairs MT2's ability to bind ligands [7].

Residue H5.46 (H1955.46 in MT1 and H2085.46 in MT2), two helical turns beneath Y5.38, distinguishing the pockets most clearly from the active and dormant structures (▶ Fig. 4e, f). The pocket size of the residue H5.46 (H1955.46 in MT1 and H2085.46 in MT2) differs the most between the inactive and active forms (▶ Fig. 4e, f). H5.46 avoiding

bound ligand forms inactive complexes with TM4 (▶ Fig. 4e, f). The toggle switch residue W6.48 (W216.48 in MT1 and W264.48 in MT2) and van der Waals contacts with the connected ligand's alkyl amide tail are formed when the ligand moves inside by 2.4 Å and flips its side chain in the active structures (▶ Fig. 4e, f). H5.46's new conformation clarifies why the H2085.46 A mutation dampened MT2 activity [27].

Despite the fact that H5.46 experiences similar conformational changes in MT1 and MT2, its functional significance seems to vary between the two receptors, as the H2085.46 (MT2) mutation only slightly decreased MT2 function whereas the H1955.46 A (MT1) mutation drastically impaired MT1 activity. Then, we docked to both receptors using the common ligands CTL 01–05-B-A0527 and 5-hydroxyethoxy-*N*-acetyltryptamine (5-HEAT) [28]. In contrast to melatonin, 5-HEAT and CTL 01–05-B-A05 have substitutions in the R1 position. 5-HEAT was able to keep a position superimposable to that of bound 2-iodomelatonin, thanks to hydrogen bonds to MT1 residues N1624.60 and Y1875.38. (▶ Fig. 4g). To conclude that 5-HEAT is an MT1 agonist, we must first determine whether or not its molecular structure is consistent with the expected position of the active pocket necessary to activate MT1.



► **Fig. 4** Activation of MT1 and MT2 receptors: **a**: The active structure of the MT1 receptor (blue) and an inactive type 1 receptor (light blue) are shown and contrasted. There are three perspectives available. In this image, the TM6 conformation of the Gs-coupled beta2 receptor (right) and the Gi-coupled opioid receptor (left) is compared to that of the MT1 molecule. Structures of active (green) and inactive (light green) MT2 are shown side by side. Three different perspectives are seen here. These images show the differences between MT1's TM1 (left) and MT2's ICL2 (right). **e–g**: There are conformational changes in MT1 motifs and other critical residues during receptor activation. Structures of active and inactive melatonin receptors 1 and 2 revealed F6.41 conformations. Gi signaling pathways were visible in I F6.41 from both MT1 and MT2 mutants. The findings are presented as the means standard deviations of three separate experiments in which wild-type receptors were used as a reference.


On the other hand, due to the dissimilar shapes of N1754.60 and Y2005.38, the MT2 antagonist 5-HEAT was not a good fit for docking in the active pocket of MT2. Induced-fit binding is probably used by 5-HEAT. Weak binding of CTL 01–05-B-A05 to MT2 was observed because the side chain of I2075.45 disrupted the stacking contact between these two molecules (► **Fig. 4i**). Notably, in light of our findings, further biopic ligand development is required to produce more focused MT1 agonists. In light of our findings, further development of the biopic ligand is required to produce more focused MT1 agonists. A feasible technique for optimizing the fit with the “longitudinal channel” would include specific substituents in the second unit.

The region known as the sub-pocket, which is located around the R3 group of the ligand and was barely distinguishable in the inactive MT1 and MT2 pockets, became more distinct in the active structures. At position 7.40 in MT1, there is a tyrosine (Y2827.40). Lucien (L2957.40) is the equivalent residue in MT2 (► **Fig. 5j**). When Y2827.40 is packed against TM1, the two adjacent residues Y2817.39 and Y2857.43 are pushed closer to the pocket's center than the corresponding residues Y2947.39 and Y2987.43 in MT2

(► **Fig. 4j**). Since MT2 has a larger sub pocket; as a result, it can accommodate ligands with bulky R3 substituents, which is in line with the chemical architectures of the majority of MT2 selective agonists [27, 29]. MT1 and MT2 receptors are structurally and functionally similar and also have unique features in their ligand binding pockets. The N4.60-Y5.38-H5.46 motif, the longitudinal channel, and the larger sub pocket in melatonin receptor type 2 could all be used as targets for the designing of melatonin subtype-selective drugs.

### Melatonin type 1 and type 2 structure signaling complex

2-Iodometelatonin, a nonselective agonist [8] and ramelteon [30] are used to obtain stable MT1 Gi-Protein complexes. Both of these compounds show high potency and affinity toward these receptors. Co-expression of G protein and receptor was studied in the insect cells. The resolution of 2-iodometelatonin and ramelteon was determined, showing global resolutions 3.1 and 3.3 Å, respectively. The assembled complex was purified for homogeneity, and cryo-EM studied their complexes for single particles. An atomic model



**Fig. 5** Signaling Pathway of MT2 receptor: Melatonin activates MT1 receptors and activates Gai decreasing cAMP second messenger and activates PI3K/Akt, PKC, and ERK pathways dependent on Gβγ. Intracellular Ca<sup>2+</sup> concentration is increased. PLC is activated by Gq coupling to melatonin. Potassium and calcium on channels are activated by melatonin and modulate neuronal action mediated and inhibit Ca<sup>2+</sup> entry through Gβγ subunits. MT2 receptors are activated by the ERK signaling pathway and Gai-dependent cAMP and inhibited cyclic guanosine monophosphate synthesis. Recruitment of α-arrestin is induced by melatonin, down streaming signaling mechanism is still unknown.

consisting of ligands MT1, Gi, and scFv1627 was built, and relatively high-quality density maps were used. The side chain of melatonin receptor type 1 and G-inhibitory protein was explained in the structure. TM1 and TM7 possess extra density between their N-terminal portions, and as a cholesterol molecule, it was changed. The agonist-bound MT2-Gi complex was studied in the same manner. The reconstituted ramelteon-bound MT2-Gi-scFv16 complex was acquainted by cryo-EM.


For high-resolution maps, the receptor stability was improved. According to previous findings, three thermostable mutations, F1293.41W, C1403.52L, and L108ECL1F, were introduced to MT2, which are not contagious to the coupling interface of G-protein and ligand binding pocket. The ligand interaction with receptor and G-proteins coupling interferes minimally with mutations [24]. An EM density map was obtained at 3.5 nominal resolution by using the triple mutant complex of ramelteon-MT2-Gi-scFv16, enabling to model ramelteon, scFv16, significant portions of the receptor, MT1 and MT2 Gi protein receptors are assembled similarly to Gi protein, GPCRS, and G-protein complexes. The ramelteon and 2-iodomelatonin ligands bound to orthostatic pockets of MT1 and MT2 receptors. MT1-Gi bound to ramelteon bound and 2-iodomelatonin are structurally identical, showing 1 Å root mean square deviation values indicating complexes of Ca atoms and 0.8 Å values indicating the Ca atoms of MT1. Ramelteon-bound MT2-Gi and MT1-Gi are structurally identical showing 1.4 roots mean square deviation of receptors Ca. The regions involved in the engagement of G-protein and the extracellular side are structurally different.

## B Melatonin's as signaling pathway

### Receptor signaling

The intrinsic melatonin receptor affinity for different types of G proteins is not yet known. The relative expression of different proteins is dependent on the coupling profile of the G protein, accounting pharmacology of the melatonin receptor bias system. MT1 and MT2 receptors inhibit Adenyl cyclase after coupling to G inhibitory proteins. Melatonin receptor type 1 co-immunoprecipitated with Gai3 and Gai2 inhibitory proteins, has the least affinity for Gq/11 proteins and does not couple to Gai1, Gaz, Gao, Ga12, or Gas proteins in HEK293 cells. The concentrations of inositol triphosphate, diacylglycerol, Ca<sup>2+</sup>, and cAMP are regulated by melatonin receptors in the cells [31]. Gα16 protein is expressed in hematopoietic cells, which illustrates the bias system [32]. Melatonin receptors type 1 and type 2 couple to Gα16 protein through Jun N-terminal kinase. In COS-7 cells, the melatonin signaling pathway is initiated [33]. In tissues and cells, Gq/11 couples to melatonin receptors endogenously in the myometrium, prostate [34], pancreatic cells and epithelial cells [35] and mesenchymal stem cells of humans [36], cells from non-mammalian organisms [37] and cells which express recombinants [38]. Ion channels and multiple pathways are regulated by melatonin. Muscle contraction is modulated by melatonin in arteries [39]. Melatonin controls the myometrium's conductance of K<sup>+</sup> channels that Ca<sup>2+</sup> activates, and the activation of the Gi/cAMP/PKA and Gq/PLC/Ca<sup>2+</sup> signaling pathways modulates the function of these channels. Activation of gene transcription and inhibition of transcriptional factor






► **Fig. 6** Signaling pathways of MT1 and MT2 receptors: Different signaling pathways are activated by melatonin depending on the presence of cell stressors or cell types. MT1 receptors are mainly involved in these signaling pathways, and MT2 receptors also participated in these pathways and were studied in neurodegenerative disorders and under oxidative stress conditions, involving melatonin modulation of mitochondrial signaling mechanisms, that is, translocation of SIRT proteins and Bcl2/Bax is regulated. The Akt/FOXO1, ERK, and JAK2 complexes activated by melatonin induce the survival of cells and regulate stem cell differentiation. These signaling pathways are inhibited by melatonin in cancer cells. Anti-inflammatory and anti-oxidative effects are regulated by the transcription factors, Nrf2, PGC1 $\alpha$ , and NF- $\kappa$ B, which depends on the activation of SIRT1. In hematopoietic cells, the JNK pathway is triggered by the coupling of MT1 to G16 protein. Expression of different miRNAs is regulated by melatonin in different types of cells, that is, cancer cells.

cAMP responsive element binding protein takes place through extracellular-signal-regulated kinase pathway at the transcriptional level. Melatonin receptors type 1 and type 2 are different only in the inhibition of cGMP synthesis during signaling. Melatonin receptor type 2 synthesizes cGMP, which is studied in human non-pigmented ciliary epithelial cells [40].

### Signaling cascades and effects

Regulation of circadian rhythm has been extensively studied and based on system bias [8]. Melatonin affects the master clock and hypothalamic suprachiasmatic nucleus neurons and mediates in a cAMP-independent manner but a Gi-dependent manner. G protein-coupled receptors are activated, rectifying K-channels, that is, Kir3 in melatonin receptors type 1 [41], and melatonin receptor type-2 mediates action through the PKC signaling pathway [42]. Both receptors modulate neuronal actions through induced cAMP synthesis by pituitary Adenyl cyclase activating peptides (PACAP) in the suprachiasmatic nucleus [43]. Melatonin mediates action in a Gi-dependent manner and modulates gene expression in the striatum (► **Fig. 6**) [19]. Melatonin type 1 receptor can affect the rate of activation of cerebellar Purkinje cells by inhibiting P-type Ca<sup>2+</sup> channels via Gi/G/PI3K/PKC signaling [44]. Synchronizing effects in the hypophyseal pars tuberalis with SCN are mediated by melatonin. In order to control the production of mPer1, mCry1, clock, and Bmal1 genes, melatonin activates a heterologous repressive mechanism via MT1 and adenosine A2B receptors and sensitizes the cAMP pathway [45]. This signaling cascade is mediated by NPAS4, a transcription factor with a Per-Arnt Sim domain, and G protein regulators [46]. It is not fully understood how melatonin regulates circadian rhythm, but it appears to vary on cell type, including Clock Gene Transcription and Post-Translational Regulation [47]. Melatonin regulates the clock machinery of the retina. The



► **Fig. 7** Physiological action of melatonin hormone.

melatonin signaling mechanism in retinal physiology is still unknown [48].

Melatonin receptors of knockout mice showed variations in the expression of genes that control clock rhythm and other genes' expression [49]. Melatonin mediates action dependent on MT1/MT2 heteromers, activating Gq/PLC/Ca<sup>2+</sup> pathway and controlling light sensitivity in the retina at night [49]; regulation of photoreceptor is dependent on the Akt/FOXO1 signaling pathway [50]. During pathological and physiological conditions, the viability of neurons is regulated by melatonin. Melatonin shows neuroprotective and antiapoptotic and different signaling pathways. Melatonin helps in cell survival, maturation, and differentiation in the stem cells and is prevented by luz indole, a competitive receptor antagonist [51]. Melatonin stimulates neural development in pluripotent stem cells by activating the PI3K/Akt pathway, while luz indole inhibits this process [52]. Melatonin increases the glucose transporter GLUT1's activity, activating the PI3K/Akt and ERK pathways in ES cells to promote

pluripotency [53, 54]. Luz indole is vulnerable to neurons and is the main cause of neuron cell death in MT1-silenced cells. Melatonin upregulates different antioxidant enzymes, that is, SOD1 and glutathione peroxidase, and plays antiapoptotic and antioxidant roles in ischemia or reperfusion [55]. Neuroprotective effects of melatonin and ago melatonin in cerebral ischemia via upregulation of nuclear factor erythroid related factor 2 and downregulation of reactive oxygen species [56]. Neu-P11 ligand, which acts on both the 5-HT and melatonin receptors, activates multiple pathways critical to neuronal survival. These include the PI3K/Akt, ERK, and JAK2 pathways [57] (► Fig. 7). Mitochondrial function and dynamics are responsible for the antioxidant and antiapoptotic effects of melatonin [15]. It activates caspase-3 and, prevents cytochrome c from being released and regulates Bcl-2 and Bax expression [58]. Bax/Bcl-2 translocation is induced by the JAK2/STAT3 pathway in cardiomyocytes [59]. By inducing ERK activation and blocking p38 MAPK in monocytes, an antiapoptotic effect is produced [60]. Sirtuin histone deacetylase (SIRT6) is activated by melatonin through mitochondrial signaling pathways [61], that is, in hepatocytes, AMP-activated protein kinase (AMPK), sirtuin 3 (SIRT3), superoxide dismutase (SOD2), and sirtuin [62]. The transcription factor PGC-1 $\alpha$  is controlled by the MT1 receptor in retinal cells [63]. The nuclear factor kappa B (NF- $\kappa$ B) pathway is inhibited by sirtuin 1 (SIRT1), which in turn causes the anti-inflammatory effects of melatonin (► Fig. 7) [64]. Melatonin-induced MT1-dependent regulation of mitochondrial function in mice models is used to treat the neurodegenerative diseases of Alzheimer's disease, Huntington's disease, and amyotrophic lateral sclerosis [6]. Cytochrome c is inhibited by melatonin in brain mitochondria through mitochondrial MT1 receptors [53]. A cell-permeable melatonin receptor agonist was employed to distinguish between the mitochondrial Gi/cAMP cascade generated by MT1 and the rest of the cell [65]. Melatonin's neuroprotective effects are under-studied and is associated with mitochondrial MT1 signaling pathways. In the cancer field, melatonin impacts system bias on melatonin receptor cascades and shows antitumor properties by inducing apoptosis and inhibiting proliferation. MT1 receptors inhibit the phosphorylation of AKT, ERK, and PKC molecules in breast cancer models and show antitumor activity [66]. In these cells, melatonin activates the p53 DNA pathway dependent on the receptor, Akt, p38 MAPK and mTOR pathways are inhibited by melatonin in ovarian cancer.

## Therapeutic application

The regulatory effects of melatonin on the sleep-wake cycle and circadian rhythm are crucial for a wide range of melatonin therapeutic applications. Due to its potential therapeutic effects, melatonin hormone is used to treat a variety of disorders, including jet lag, insomnia, circadian rhythm disorders, mood disorders, cancer, cardiovascular diseases, and neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, as well as other seasonal affective disorders.

### Cardiovascular system

#### Lipids metabolism

Melatonin reduces high serum total cholesterol and triglyceride levels in the blood. It improves lipid metabolism by decreasing low-density lipoprotein and hence maintains lipid profile [67].

#### Blood Pressure

Melatonin intake decreases systolic and diastolic blood pressure at night. It also decreases nocturnal systolic blood pressure [68].

#### Ischemia/reperfusion injury

Consuming melatonin reduces the severity of cardiac marker injury and myocardial infarction size. It lowers heart rate by increasing ejection fraction. Melatonin intake improves blood pressure, glycaemic, and lipid in patients suffering from chronic heart diseases [69].

#### Heart Failure

Owing to antioxidant and antiapoptotic properties, melatonin intake decreases cardiac fibrosis in nonischemic heart failure. Its intake prevents myocardial infarction [70].

### Nervous System

#### Ischemic stroke

Melatonin intake is helpful in decreasing infarct volume and brain edema and improving neurologic score [71].

#### Alzheimer's disease

Melatonin intake is helpful in improving sleep quality and cognitive function in the brain. Its intake treats sleep disorders associated with amnesia, sundowning, and Alzheimer's diseases [72].

#### Parkinson's disease

As it delays the degeneration of dopaminergic neurons in the substantia nigra, melatonin intake is beneficial in the treatment of Parkinson's disease. Cognitive dysfunction, anxiety, depression, and sleep quality all improve as a result [73].

#### Epilepsy

Melatonin improves sleep behavior in epilepsy patients [74].

#### Migraine

Melatonin is used to treat migraine and prophylaxis in both adults and children [75].

#### Chronic tension-type headache

Melatonin intake improves sleep quality and prevents headache and tension [76].

#### Traumatic brain injury and spinal cord injury

Melatonin is used to treat sleep disturbances in patients with traumatic brain injury who report feeling anxious [77].

### Reproductive system

#### Erectile dysfunction

Consuming melatonin enhances the corpus cavernosum's ability to contract and relax. It improves endothelial density and erectile function [78].

#### Female reproductive system

Melatonin intake improves fertilization rate. It increases progesterone production in the corpus luteum [79].

## Gastrointestinal system

### Gastroesophageal reflux disease and gastrointestinal ulcer

Melatonin provides protection against mucosa oxidative damage in different types of gastrointestinal tract ulcers, reduces relaxation duration, and increases gastrin [80].

### Irritable bowel syndrome

Melatonin decreases abdominal pain, bloating, and constipation and increases rectal pressure [81].

### Hepatic steatosis

Melatonin lowers liver cholesterol, triglycerides, serum AST and ALT levels in hepatic steatosis patients [82].

### Hepatoprotective effects

Hemorrhagic shock, ischemia-reperfusion injury, liver damage, ionizing radiation, and *Schistosoma mansoni* infection are all diminished by melatonin [83].

## Renal system

### Reno protective effects

Melatonin protects against radiation-, folic acid-, aminoglycoside-, contrast-mediated-, and nephrotoxicity-induced by these agents. It reduces creatinine and blood urea nitrogen levels [84].

### Sepsis-induced renal injury

Melatonin intake decreases inflammasome activation [85].

## Dermatology

Melatonin protects against UV-light-induced damage by preventing the production of free radicals, erythema caused by natural sunlight, and radioprotective effects. It exhibits antiaging properties, enhances hydration, and lessens the roughness of the skin [86].

### Fibromyalgia

Melatonin intake improves pain level and fibromyalgia [87].

### Autism spectrum disorder

Consuming melatonin lowers mid-sleep awakenings, improves sleep quality, and lengthens total sleep time [88].

### Mood disorder

Melatonin diminishes sleep disorders linked to a depressed mood [89].

## Oncology

### Breast cancer

Due to its antiestrogenic effects, which lessen unwanted side effects, melatonin adjuvant therapy is used for patients who are at risk of developing ER-positive breast cancer [90].

### Ovarian cancer

During chemotherapy, melatonin provides protection to ovaries and fertility preservation [91].

### Lung cancer

Melatonin lessens harm to the ileum, colon, liver, and lungs. It lessens radiation-induced lung injury and modulates the effectiveness of DNA repair in humans as well as the genotoxic activity of irinotecan [92].

### Colorectal cancer

Because urosolic acid has antiproliferative and pro-apoptotic effects on colon cancer cells, melatonin is used to treat this disease [93].

## Viral syndromes

### Respiratory Syncytial Virus

The acute lung oxidative injury brought on by respiratory syncytial virus is lessened by melatonin [94].

### Viral myocarditis

Melatonin is used for the preservation of cardiac functions and for repression of virus-induced cardiomyocyte apoptosis. It inhibits apoptosis, regulates the rate of autophagy, and maintains mitochondrial dysfunction [95].

### Venezuelan equine encephalitis

Melatonin intake increases survival rate by reducing virus load in the brain and serum [96].

### Encephalomyelitis virus

Melatonin is used to treat encephalomyelitis by preventing death and paralysis [97].

### Semliki forest virus

Melatonin lowers viremia and postpones disease and death [98].

### COVID-19

Consuming melatonin prolongs survival time by reducing oxidative damage and slowing down the release of cytokines [99].

## Future prospects

Future directions in studying the signaling pathways and receptors for the melatonin hormone appear promising. To better comprehend the signaling pathways underlying melatonin action, the structure of the MT1 and MT2 receptors in association with various ligands and signaling molecules must be determined. Recent research has focused on the implicit role of the MT1 and MT2 receptors in a variety of sleep, cancer, and metabolic disorders. Creating new medications and adjusting melatonin's signaling pathways to treat complaints. Just two examples of the signaling pathways that interact with melatonin signaling are the cAMP and mitogen-activated protein kinase (MAPK) pathways. To find new signaling pathways, researchers are examining how the melatonin hormone binds to receptors that are similar to orphan GPCRs. More study is required to determine new therapeutic targets for melatonin and its analogs. More research is required to fully comprehend its mechanisms of action and to maximize its therapeutic application. Downstreaming signaling mechanism is still unknown. All studies about melatonin effects were assessed in in vivo and in vitro testing and preclinical trial but lacked

significant clinical trials. So, there is a huge need to conduct clinical trials to fully understand long-term melatonin's physiological effects. The signaling mechanism of melatonin receptors, their structures and their interaction with the melatonin hormone are still unknown, so there are a lot of unexplored future directions for researchers. Researchers may be able to develop potent new treatments for a variety of diseases and disorders if they learn more about the receptors involved and the signals they send. Melatonin's regulatory effects on several physiological systems make it promising for a variety of therapeutic purposes.

## Conclusion

Melatonin, a hormone produced by the pineal gland, controls circadian rhythms, sleep-wake cycles, and other physiological processes. G-protein-coupled receptors (GPCRs), of which two are known as MT1 and MT2, mediate melatonin's effects on the body. Molecular modeling and X-ray crystallography are two methods that have been used to determine the structures of the melatonin type 1 and type 2 receptors. Each of these receptors has seven transmembrane domains that connect the intracellular and extracellular domains together. A conformational change that occurs when melatonin binds to its receptors causes downstream signaling pathways to become active. Recent research continues to focus on the receptors and signaling pathways that melatonin mediates. Due to the multifactorial pathophysiology of melatonin, the majority of the studies were preclinical, in vitro, with small sample sizes, and concentrated on short-term results. Additionally, more research is required because inadequate study methods constrain decision-making regarding this new use for this medication. Before applying this knowledge to clinical practice, more clinical trials with larger sample sizes, precise dosages, and longer durations are required to confirm the long-term side effects of melatonin. More investigations of the receptors and signaling mechanisms that melatonin uses to exert its beneficial therapeutic effects are required.

## Acknowledgement

We would like to express our deep gratitude to Dr. Wang Fu, professor, School of Basic Medicine, Xian Jiaotong University, China and Dr. Haq Nawaz, assistant professor, Department of Biochemistry, Bahauddin Zakariya University, Multan, Pakistan for their scholarly guidance. We also greatly appreciate the help of Mr. Sajid Ali, PhD candidate at Xian Jiaotong University, China for his constructive suggestions and technical guidance. Finally, we are grateful to all of those with whom we have had the pleasure of working during this and other related projects.

## Remarks

A previous version of this manuscript has been deposited on a pre-print server [100].

## Conflict of Interest

The authors declare that they have no conflict of interest.

## References

- do Amaral FG, Cipolla-Neto J. A brief review about melatonin, a pineal hormone. *Arch Endocrinol Metab* 2018; 62: 472–479
- Ruan W, Yuan X, Eltzhig HK. Circadian rhythm as a therapeutic target. *Nat Rev Drug Discov* 2021; 20: 287–307
- Radogna F, Albertini MC, De Nicola M et al. Melatonin promotes Bax sequestration to mitochondria reducing cell susceptibility to apoptosis via the lipoxygenase metabolite 5-hydroxyecosatetraenoic acid. *Mitochondrion* 2015; 21: 113–121
- Nikolaev G, Robeva R, Konakchieva R. Membrane melatonin receptors activated cell signaling in physiology and disease. *Int J Mol Sci* 2021; 23: 471
- Bach V, Delanaud S, Barcat L et al. Distal skin vasodilation in sleep preparedness, and its impact on thermal status in preterm neonates. *Sleep Med* 2019; 60: 26–30
- Li D, Smith D, Hardeland R et al. Melatonin receptor genes in vertebrates. *Int J Mol Sci* 2013; 14: 11208–11223
- Sheng W, Jin M, Pan G et al. Cellular localization of melatonin receptor Mel1b in pigeon retina. *Neuropeptides* 2019; 78: 101974
- Dubocovich ML, Delagrange P, Krause DN et al. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. *Pharmacol Rev* 2010; 62: 343–380
- Gombert M, Codoñer-Franch P. Melatonin in early nutrition: long-term effects on cardiovascular system. *Int J Mol Sci* 2021; 22: 6809
- Tan D-X, Manchester L, Esteban-Zubero E et al. Melatonin as a potent and inducible endogenous antioxidant: synthesis and metabolism. *Molecules* 2015; 20: 18886–18906
- Basler M, Jetter A, Fink D et al. Urinary excretion of melatonin and association with breast cancer: meta-analysis and review of the literature. *Breast Care* 2014; 9: 182–187
- Jockers R, Delagrange P, Dubocovich ML et al. Update on melatonin receptors: IUPHAR Review 20. *Br J Pharmacol* 2016; 173: 2702–2725
- Argueta J, Solís-Chagoyán H, Estrada-Reyes R et al. Further evidence of the melatonin calmodulin interaction: effect on CaMKII activity. *Int J Mol Sci* 2022; 23: 2479
- Ma N, Zhang J, Reiter RJ, Ma X. Melatonin mediates mucosal immune cells, microbial metabolism, and rhythm crosstalk: A therapeutic target to reduce intestinal inflammation. *Med Res Rev* 2020; 40: 606–632
- Tan D-X, Manchester L, Qin L, Reiter R. Melatonin: a mitochondrial targeting molecule involving mitochondrial protection and dynamics. *Int J Mol Sci* 2016; 17: 2124
- Li DY, Smith DG, Hardeland R et al. Melatonin receptor genes in vertebrates. *Int J Mol Sci* 2013; 14: 11208–11223
- López-Canul M, Comai S, Domínguez-López S et al. Antinociceptive properties of selective MT2 melatonin receptor partial agonists. *Eur J Pharmacol* 2015; 764: 424–432
- Emet M, Ozcan H, Ozel L et al. A review of melatonin, its receptors and drugs. *Eurasian J Med* 2016; 48: 135
- Imbesi M, Arslan AD, Yildiz S et al. The melatonin receptor MT1 is required for the differential regulatory actions of melatonin on neuronal 'clock' gene expression in striatal neurons in vitro. *J Pineal Res* 2009; 46: 87–94
- Wood S, Loudon A. Clocks for all seasons: unwinding the roles and mechanisms of circadian and interval timers in the hypothalamus and pituitary. *J Endocrinol* 2014; 222: R39
- Pandiperumal S, Trakht I, Srinivasan V et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. *Prog Neurobiol* 2008; 85: 335–353

- [22] Liu D, Wei N, Man H-Y et al. The MT2 receptor stimulates axonogenesis and enhances synaptic transmission by activating Akt signaling. *Cell Death Differ* 2015; 22: 583–596
- [23] Hazlerigg D, Loudon A. New insights into ancient seasonal life timers. *Curr Biol* 2008; 18: R795–R804
- [24] Johansson LC, Stauch B, McCorvy JD et al. XFEL structures of the human MT2 melatonin receptor reveal the basis of subtype selectivity. *Nature* 2019; 569: 289–292
- [25] Stauch B, Johansson LC, McCorvy JD et al. Structural basis of ligand recognition at the human MT1 melatonin receptor. *Nature* 2019; 569: 284–288
- [26] Pala D, Lodola A, Bedini A et al. Homology models of melatonin receptors: challenges and recent advances. *Int J Mol Sci* 2013; 14: 8093–8121
- [27] Chan KH, Tse LH, Huang X, Wong YH. Molecular basis defining the selectivity of substituted isoquinolinones for the melatonin MT2 receptor. *Biochem Pharmacol* 2020; 177: 114020
- [28] Bourin M. Physiology and pharmacology of melatonin. In: Gargiulo PÁ, Mesones Arroyo HL (eds). *Psychiatry and neuroscience update*. Springer International Publishing; Cham: 2021: 261–277
- [29] Zlotos Darius P, Jockers R, Cecon E et al. MT<sub>1</sub> and MT<sub>2</sub> Melatonin receptors: ligands, models, oligomers, and therapeutic potential. *J Med Chem* 2014; 57: 3161–3185
- [30] Nishiyama K, Hirai K. The melatonin agonist ramelteon induces duration-dependent clock gene expression through cAMP signaling in pancreatic INS-1  $\beta$ -cells. *PLoS One* 2014; 9: e102073
- [31] Peschke E, Bähr I, Mühlbauer E. Experimental and clinical aspects of melatonin and clock genes in diabetes. *J Pineal Res* 2015; 59: 1–23
- [32] Cecon E, Oishi A, Jockers R. Melatonin receptors: molecular pharmacology and signalling in the context of system bias. *Br J Pharmacol* 2018; 175: 3263–3280
- [33] Carbajo-Pescador S, García-Palomo A, Martín-Renedo J et al. Melatonin modulation of intracellular signaling pathways in hepatocarcinoma HepG2 cell line: role of the MT1 receptor: Melatonin receptors in human hepatocarcinoma cells. *J Pineal Res* 2011; 51: 463–471
- [34] Saikia S, Bordoloi M, Sarmah R. Established and in-trial GPCR families in clinical trials: a review for target selection. *Curr Drug Targets* 2019; 20: 522–539
- [35] Bähr I, Mühlbauer E, Albrecht E, Peschke E. Evidence of the receptor-mediated influence of melatonin on pancreatic glucagon secretion via the G $\alpha$ q protein-coupled and PI3K signaling pathways: Melatonin receptor and glucagon secretion. *J Pineal Res* 2012; 53: 390–398
- [36] Lee S-J, Jung YH, Oh SY et al. Melatonin enhances the human mesenchymal stem cells motility via melatonin receptor 2 coupling with G $\alpha$ q in skin wound healing. *J Pineal Res* 2014; 57: 393–407
- [37] Borges R, Johnson WE, O'Brien SJ et al. The role of gene duplication and unconstrained selective pressures in the melanopsin gene family evolution and vertebrate circadian rhythm regulation. *PLoS One* 2012; 7: e52413
- [38] Cecon E, Boutin JA, Jockers R. Molecular characterization and pharmacology of melatonin receptors in animals. *Receptors* 2023; 2: 127–147
- [39] Valenzuela-Melgarejo FJ, Lagunas C, Carmona-Pastén F et al. Supraphysiological role of melatonin over vascular dysfunction of pregnancy, a new therapeutic agent? *Front Physiol* 2021; 12: 767684
- [40] Dortch-Carnes J, Tosini G. Melatonin receptor agonist-induced reduction of SNP-released nitric oxide and cGMP production in isolated human non-pigmented ciliary epithelial cells. *Exp Eye Res* 2013; 107: 1–10
- [41] Karamitri A, Jockers R. Melatonin in type 2 diabetes mellitus and obesity. *Nat Rev Endocrinol* 2019; 15: 105–125
- [42] Lee S-J, Jung YH, Oh SY et al. Melatonin enhances the human mesenchymal stem cells motility via melatonin receptor 2 coupling with G $\alpha$ q in skin wound healing. *J Pineal Res* 2014; 57: 393–407
- [43] Pfeffer M, Rauch A, Korf H-W, Von Gall C. The endogenous melatonin (MT) signal facilitates reentrainment of the circadian system to light-induced phase advances by acting upon MT2 receptors. *Chronobiol Int* 2012; 29: 415–429
- [44] Zhang Y, Li H, Pu Y et al. Melatonin-mediated inhibition of Purkinje neuron P-type Ca<sup>2+</sup> channels in vitro induces neuronal hyperexcitability through the phosphatidylinositol 3-kinase-dependent protein kinase C delta pathway. *J Pineal Res* 2015; 58: 321–334
- [45] Owino S, Sánchez-Bretaña A, Tchic C et al. Nocturnal activation of melatonin receptor type 1 signaling modulates diurnal insulin sensitivity via regulation of PI 3K activity. *J Pineal Res* 2018; 64: e12462
- [46] West A, Dupré SM, Yu L et al. *Npas4* is activated by melatonin, and drives the clock gene *Cry1* in the ovine pars tuberalis. *Mol Endocrinol* 2013; 27: 979–989
- [47] Vriend J, Reiter RJ. Melatonin feedback on clock genes: a theory involving the proteasome. *J Pineal Res* 2015; 58: 1–11
- [48] Wiechmann AF, Sherry DM. Role of melatonin and its receptors in the vertebrate retina. *Int Rev Cell Mol Biol* 2013; 300: 211–242
- [49] Hiragaki S, Baba K, Coulson E et al. Melatonin signaling modulates clock genes expression in the mouse retina. *PLoS One* 2014; 9: e106819
- [50] Ganesini C, Hiragaki S, Laurent V et al. Cone viability is affected by disruption of melatonin receptors signaling. *Investig Ophthalmology Vis Sci* 2016; 57: 94
- [51] Beker MC, Caglayan B, Caglayan AB et al. Interaction of melatonin and Bmal1 in the regulation of PI3K/AKT pathway components and cellular survival. *Sci Rep* 2019; 9: 19082
- [52] Shu T, Wu T, Pang M et al. Effects and mechanisms of melatonin on neural differentiation of induced pluripotent stem cells. *Biochem Biophys Res Commun* 2016; 474: 566–571
- [53] Wang X, Sirianni A, Pei Z et al. The melatonin MT1 receptor axis modulates mutant huntingtin-mediated toxicity. *J Neurosci* 2011; 31: 14496–14507
- [54] Wu H, Song C, Zhang J et al. Melatonin-mediated upregulation of GLUT1 blocks exit from pluripotency by increasing the uptake of oxidized vitamin C in mouse embryonic stem cells. *FASEB J* 2017; 31: 1731–1743
- [55] Parada E, Buendia I, León R et al. Neuroprotective effect of melatonin against ischemia is partially mediated by alpha-7 nicotinic receptor modulation and HO-1 overexpression. *J Pineal Res* 2014; 56: 204–212
- [56] Ding K, Wang H, Xu J et al. Melatonin stimulates antioxidant enzymes and reduces oxidative stress in experimental traumatic brain injury: the Nrf2–ARE signaling pathway as a potential mechanism. *Free Radic Biol Med* 2014; 73: 1–11
- [57] Buendia I, Gómez-Rangel V, González-Lafuente L et al. Neuroprotective mechanism of the novel melatonin derivative Neu-P11 in brain ischemia related models. *Neuropharmacology* 2015; 99: 187–195
- [58] Mortezaee K, Najafi M, Farhood B et al. Modulation of apoptosis by melatonin for improving cancer treatment efficiency: an updated review. *Life Sci* 2019; 228: 228–241
- [59] Duan W, Yang Y, Yi W et al. New role of JAK2/STAT3 signaling in endothelial cell oxidative stress injury and protective effect of melatonin. *PLoS One* 2013; 8: e57941
- [60] Hardeland R. Melatonin in aging and disease - multiple consequences of reduced secretion, options and limits of treatment. *Aging Dis* 2012; 3: 194–225

- [61] Mayo JC, Sainz RM, González Menéndez P et al. Melatonin and sirtuins: a "not-so unexpected" relationship. *J Pineal Res* 2017; 62: e12391
- [62] Guo P, Pi H, Xu S et al. Melatonin improves mitochondrial function by promoting MT1/SIRT1/PGC-1 alpha-dependent mitochondrial biogenesis in cadmium-induced hepatotoxicity in vitro. *Toxicol Sci* 2014; 142: 182–195
- [63] Kunst S, Wolloscheck T, Kelleher DK et al. *Pgc-1α* and *Nr4a1* are target genes of circadian melatonin and dopamine release in murine retina. *Investig Ophthalmol Vis Sci* 2015; 56: 6084
- [64] Tajes M, Gutierrez-Cuesta J, Ortuño-Sahagun D et al. Anti-aging properties of melatonin in an in vitro murine senescence model: involvement of the sirtuin 1 pathway. *J Pineal Res* 2009; 47: 228–237
- [65] Gbahou F, Cecon E, Viault G et al. Design and validation of the first cell-impermeant melatonin receptor agonist: cell-impermeant melatonin receptor agonist. *Br J Pharmacol* 2017; 174: 2409–2421
- [66] Hill SM, Belancio VP, Dauchy RT et al. Melatonin: an inhibitor of breast cancer. *Endocr Relat Cancer* 2015; 22: R183–R204
- [67] Koziróg M, Poliwczak AR, Duchnowicz P et al. Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome: melatonin in metabolic syndrome. *J Pineal Res* 2011; 50: 261–266
- [68] Borghi C, Cicero AFG. Nutraceuticals with a clinically detectable blood pressure-lowering effect: a review of available randomized clinical trials and their meta-analyses: antihypertensive nutraceuticals. *Br J Clin Pharmacol* 2017; 83: 163–171
- [69] Baker J, Kimpinski K. Role of melatonin in blood pressure regulation: an adjunct anti-hypertensive agent. *Clin Exp Pharmacol Physiol* 2018; 45: 755–766
- [70] Nduhirabandi F, Maarman G. Melatonin in heart failure: a promising therapeutic strategy? *Molecules* 2018; 23: 1819
- [71] Liu Z, Ran Y, Qie S et al. Melatonin protects against ischemic stroke by modulating microglia/macrophage polarization toward anti-inflammatory phenotype through STAT3 pathway. *CNS Neurosci Ther* 2019; 25: 1353–1362
- [72] Lin L, Huang Q-X, Yang S-S et al. Melatonin in Alzheimer's disease. *Int J Mol Sci* 2013; 14: 14575–14593
- [73] Yildirim FB, Ozsoy O, Tanriover G et al. Mechanism of the beneficial effect of melatonin in experimental Parkinson's disease. *Neurochem Int* 2014; 79: 1–11
- [74] Banach M, Gurdziel E, Jędrzych M, Borowicz KK. Melatonin in experimental seizures and epilepsy. *Pharmacol Rep* 2011; 63: 1–11
- [75] Fallah R, Shoroki F, Ferdosian F. Safety and efficacy of melatonin in pediatric migraine prophylaxis. *Curr Drug Saf* 2015; 10: 132–135
- [76] Danilov AB, Danilov AB, Kurushina OV et al. Safety and efficacy of melatonin in chronic tension-type headache: a post-marketing real-world surveillance program. *Pain Ther* 2020; 9: 741–750
- [77] Grima NA, Rajaratnam SMW, Mansfield D et al. Efficacy of melatonin for sleep disturbance following traumatic brain injury: a randomised controlled trial. *BMC Med* 2018; 16: 8
- [78] Tavukçu HH, Şener TE, Tinay İ et al. Melatonin and tadalafil treatment improves erectile dysfunction after spinal cord injury in rats. *Clin Exp Pharmacol Physiol* 2014; 41: 309–316
- [79] Hu K-L, Ye X, Wang S, Zhang D. Melatonin application in assisted reproductive technology: a systematic review and meta-analysis of randomized trials. *Front Endocrinol* 2020; 11: 160
- [80] Kandil TS, Mousa AA, El-Gendy AA, Abbas AM. The potential therapeutic effect of melatonin in gastro-esophageal reflux disease. *BMC Gastroenterol* 2010; 10: 7
- [81] Chojnacki C, Walecka-Kapica E, Lokieć K et al. Influence of melatonin on symptoms of irritable bowel syndrome in postmenopausal women. *Endokrynol Pol* 2013; 64: 114–120
- [82] Bahrami M, Cheraghpour M, Jafarirad S et al. The effect of melatonin on treatment of patients with non-alcoholic fatty liver disease: a randomized double blind clinical trial. *Complement Ther Med* 2020; 52: 102452
- [83] Mathes AM. Hepatoprotective actions of melatonin: possible mediation by melatonin receptors. *World J Gastroenterol* 2010; 16: 6087
- [84] Kim JW, Jo J, Kim J-Y et al. Melatonin attenuates cisplatin-induced acute kidney injury through dual suppression of apoptosis and necroptosis. *Biology* 2019; 8: 64
- [85] Dai W, Huang H, Si L et al. Melatonin prevents sepsis-induced renal injury via the PINK1/Parkin1 signaling pathway. *Int J Mol Med* 2019; 44: 1197–1204
- [86] Rusanova I, Martínez-Ruiz L, Florido J et al. Protective effects of melatonin on the skin: future perspectives. *Int J Mol Sci* 2019; 20: 4948
- [87] Danilov A, Kurganova J. Melatonin in chronic pain syndromes. *Pain Ther* 2016; 5: 1–17
- [88] Maras A, Schroder CM, Malow BA et al. Long-term efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. *J Child Adolesc Psychopharmacol* 2018; 28: 699–710
- [89] Serfaty MA, Osborne D, Buszewicz MJ et al. A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6 mg) or placebo for sleep disturbance and depressed mood. *Int Clin Psychopharmacol* 2010; 25: 132–142
- [90] González-González A, Mediavilla M, Sánchez-Barceló E. Melatonin: A molecule for reducing breast cancer risk. *Molecules* 2018; 23: 336
- [91] Wang N, Li H, Zhu Y et al. Melatonin protects against epirubicin-induced ovarian damage. *J Reprod Dev* 2020; 66: 19–27
- [92] Tahamtan R, Shabestani Monfared A, Tahamtani Y et al. Radioprotective effect of melatonin on radiation-induced lung injury and lipid peroxidation in rats. *Cell J* 2015; 17: 111–120
- [93] Wang J, Guo W, Chen W et al. Melatonin potentiates the antiproliferative and pro-apoptotic effects of ursolic acid in colon cancer cells by modulating multiple signaling pathways. *J Pineal Res* 2013; 54: 406–416
- [94] Huang S-H, Cao X-J, Liu W et al. Inhibitory effect of melatonin on lung oxidative stress induced by respiratory syncytial virus infection in mice. *J Pineal Res* 2010; 48: 109–116
- [95] Ouyang H, Zhong J, Lu J et al. Inhibitory effect of melatonin on Mst1 ameliorates myocarditis through attenuating ER stress and mitochondrial dysfunction. *J Mol Histol* 2019; 50: 405–415
- [96] Montiel M, Bonilla E, Valero N et al. Melatonin decreases brain apoptosis, oxidative stress, and CD200 expression and increased survival rate in mice infected by Venezuelan equine encephalitis virus. *Antivir Chem Chemother* 2015; 24: 99–108
- [97] Boga JA, Coto-Montes A, Rosales-Corral SA et al. Beneficial actions of melatonin in the management of viral infections: a new use for this "molecular handyman"?: melatonin and viral infections. *Rev Med Virol* 2012; 22: 323–338
- [98] Escribano BM, Muñoz-Jurado A, Caballero-Villarraso J et al. Protective effects of melatonin on changes occurring in the experimental autoimmune encephalomyelitis model of multiple sclerosis. *Mult Scler Relat Disord* 2022; 58: 103520
- [99] Cross KM, Landis DM, Sehgal L, Payne JD. Melatonin for the early treatment of COVID-19: a Narrative review of current evidence and possible efficacy. *Endocr Pract* 2021; 27: 850–855
- [100] <https://www.authorea.com/users/633263/articles/651744-revealing-melatonin-s-mysteries-receptors-signaling-pathways-and-therapeutics-applications>